3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Small Cell Lung Carcinoma
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Surveys and Questionnaires
5
Nivolumab
5
pembrolizumab
3
atezolizumab
3
Radiosurgery
3
pralsetinib
2
pertuzumab
2
cobimetinib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Exercise
2
Drug Therapy
2
trastuzumab deruxtecan
1
trametinib
1
tepotinib
1
talazoparib
1
selpercatinib
1
repotrectinib
1
remune
1
ponatinib
1
pemigatinib
1
pazopanib
1
palbociclib
1
osimertinib
1
motexafin gadolinium
1
montanide ISA 51
1
itacitinib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
ponatinib
×
Thoracic
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled